Yup. Apparently, our previous post on data exclusivity and the like, will also effect prices in places like Canada as well.
Provisions in a new trade deal being negotiated between Canada and the European Union could add about $2.8-billion a year in costs to Canadian drug plans if implemented, a new report warns.
The estimate includes $1.3-billion more for public drug plans and $1.5-billion for private drug plans.
This is because the EU is asking for a number of things, including lengthening the terms of data exclusivity. Given that in Canada, “Generics account for 54 per cent of prescription drugs and brand-name drugs 46 per cent,” moves such as this will obviously prevent or at least greatly delay the existence of generics in the market. Crucially, and what is a bit dodgy about this whole thing, is that such moves will do these things even if a patent has already expired. It’s just another sneaky way for the pharmaceutical industry to keep control.
Anyway, read the whole Globe and Mail article at the link below.